BioSpace News Archive

etherna announced today that Steffen Helmling, PhD has been appointed Chief Business Officer.

Parse Biosciences announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale.

FX received FDA clearance to launch the next revolution of their distal interlocking stems. FX adds the lengths 120mm, 180mm and 200mm cementless interlocking stems to further complement the previously cleared 70mm (not interlocking) FX V135™ mini.

IMUNON, Inc. announces that President and Chief Executive Officer Dr. Corinne Le Goff presented an overview of IMUNON’s business progress and its progress to an audience of investors and biopharmaceutical professionals at the BIO 2023 International Convention underway in Boston.

DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST).

Biora Therapeutics, Inc. (Nasdaq: BIOR) today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (“Dermata” or the “Company”) today announced that positive results from its DMT310 Phase 2b study of its once-weekly topical treatment in patients with moderate-to-severe acne vulgaris was published in the prestigious, peer-reviewed Journal of the American Academy of Dermatology (JAAD).

Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

StageZero Life Sciences, Ltd (TSX: SZLS) (OTCQB: SZLSF) (“StageZero” or the “Company”) is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company’s management information circular dated April 28 2023 (the “Circular”)

Qosina is happy to announce its partnership with Carolina Components Group, a leading supplier of primary and support production materials for the pharmaceutical and biotech manufacturing industries.